HAIFA, Israel – Apr. 8, 2024 – Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, “System and Methods for Immune Cells Expansion and Activation in Large Scale.”
Pluri’s novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
Pluri’s patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation. By addressing the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues, Pluri’s technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success. With a commitment to pushing the boundaries of possibility, Pluri is poised to lead the charge towards realizing the full potential of allogeneic cell therapy, ultimately transforming the lives of patients worldwide.
“We believe that our continued investment in technology, paired with two decades of expertise, enable us to develop the next generation of medical treatments,” said Yaky Yanay, CEO and President of Pluri. “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies. By harnessing the power of our proprietary technology, we are not only advancing the possibilities of allogeneic cell therapy, we are also reaffirming our commitment to improving patient outcomes worldwide.”
The patented technology addresses the global immune cell engineering market size which is expected to reach $11.66 billion by 2030, from $2.82 billion in 2023, at a CAGR of 22.5% during the forecast period.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell- based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its technology, that its technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success, the belief that its continued investment in technology, paired with two decades of expertise, enable it to develop the next generation of medical treatments, that its patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies, and the expected growth in the allogeneic cell therapy market.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know- how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries
HAIFA, Israel, March 28, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced leadership from its business verticals will be presenting at, and participating in, the following conferences:
Conference: MIW, Germany-Israel Technology
Date: April 10, 2024 Location: Berlin
Ms. Michal Ogolnik, leader of Pluri’s cell-based coffee business, will be presenting at MIW.
Pluri’s Chief Executive Officer & President, Yaky Yanay, will also attend.
Pluri’s cell-based coffee business is part of its PluriAgtech business vertical, which deploys its world-leading 3D cell expansion technology platform to reshape the agricultural landscape and redefine the possibilities of sustainable crop production.
Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation. The Company is leveraging two decades of experience and know-how in cell manufacturing to drive the future of coffee science.
By utilizing its eco-efficient mass scale production methods, Pluri offers reduced carbon footprint through cultivation, lowering resources while increasing yield for one of the world’s most traded food commodities.
Conference: ATiO Conference 2024
Date: April 10-12, 2024 Location: Berlin
Pluri’s Chief Executive Officer & President Yaky Yanay will participate in a panel of discussions and Chief Business Development Officer of Pharma Efrat Kaduri will attend the event.
Advanced Therapies in Orthopedics Foundation (ATiO) is an international specialist society founded as a non-profit association. The event is dedicated to new perspectives and possibilities in the field of advanced therapies in orthopedics and will include a discussion between key opinion leaders in research, clinics, finance and corporate.
Pluri’s cell therapy product, PLX-PAD, will be evaluated as potential treatment for knee osteoarthritis (OA) as a part of the PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis) collaboration led by Charité Berlin and supported by the EU Horizon Europe program. PLX-PAD is a multifactorial therapy product candidate with robust clinical data. It demonstrated increased muscle strength in two clinical studies and is believed to induce systemic anti-inflammatory effect and to reduce post-operative oxidative stress.
Conference: Biomed Israel
Date: May 21-23, 2024
Location: Tel Aviv
Pluri’s leadership will attend the event.
Conference: Bio International Convention
Date: June 3-6, 2024 Location: San Diego
Recently launched in January of 2024, PluriCDMO helps innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector by offering manufacturing support from the preclinical and development stages to late stage clinical and commercial production, including fill and finish and logistics.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond.
Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses its potential future service agreements, the potential benefits of its technology and that its cell therapy product, PLX-PAD, will be evaluated as a treatment for knee osteoarthritis.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – March [27], 2024 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share (the “Common Shares”) at a ratio of 1-for- 8 is expected to be implemented at market open on April 1, 2024.
The Company’s Common Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on April 1, 2024, under the Company’s existing trading symbol “PLUR”, but will trade under a new CUSIP Number, 72942G203.
After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”). In addition, the authorized capital shares of the Company are being reduced from 300,000,000 Common Shares to 37,500,000 Common Shares as a result of the Reverse Share Split and pursuant to Nevada Revised Statutes (NRS) Section 78.207. No fractional shares will be issued as a result of the reverse split as any fractional shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.
The Board of Directors of the Company approved the action in accordance with Nevada law (NRS Section 78.207). No additional Company or shareholder approval is required because both the number of authorized Common Shares and the number of outstanding Common Shares will be proportionally reduced as a result of the Reverse Share Split, the Reverse Share Split will not adversely affect any other class of shares of the Company and the Company will not pay money or issue scrip to shareholders who would otherwise be entitled to receive a fractional share as a result of the reverse split.
The reverse split will not impact any shareholder’s percentage ownership of Pluri or voting power, except for minimal effects resulting from the treatment of fractional shares.
All options, unvested shares of restricted stock, restricted stock units and warrants of the Company outstanding prior to the split will be appropriately adjusted.
Equiniti Trust Company, LLC, will act as the exchange agent for the reverse split. Please contact Equiniti Trust Company, LLC for further information at (718) 921-8200.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability.
The Company’s technology platform, a patented and validated state-of- the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the implementation of the reverse share split.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
HAIFA, Israel – March 21, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today addressed the price volatility challenge detailed in the International Coffee Organization’s (ICO) 2024 Market Report (the “Report”) According to the Report, one of the factors creating price volatility is the erratic weather conditions across the globe; from frost in Brazil in 2021 to the El Niño phenomenon expected to worsen heatwaves in Vietnam in 2024. Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.
Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions. Pluri recently announced the launch of its cell-based coffee, its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry. The Company’s cell production method grows coffee quickly and reliably in an environmentally sustainable, cost- effective, tightly controlled fully automated manufacturing process that is highly scalable. Pluri’s cell-based coffee is estimated to slash water usage by 98% throughout the entire supply chain and reduce farmland usage by 95% as compared to traditional growing methods.
To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.
“Pluri’s proprietary method for producing coffee aims to produce a better product with regards to taste, texture, scent, and sustainability,” stated Pluri’s CEO and President Yaky Yanay. “Our solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability, price stability and saving everyone’s favorite beverage.”
Learn more about Pluri’s innovative cell-based coffee technology by visiting our website.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the potential benefits of its cell- based coffee and that its solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability and price stability.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – March 19, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.
Conference: Bio-Europe Spring Date: March 18-20, 2024 Location: Barcelona
Pluri’s Chief Business Development Officer-Pharma Efrat Kaduri will attend the event.
BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.
Conference: Advanced Therapies 2024
Date: March 19-20, 2024 Location: London
Pluri’s Chief Technology Officer Lior Raviv will participate in a panel discussion titled: Points to consider when building supply chain operations from scratch on Tuesday, March 19, 2024 at 1:40 PM.
He will also give a presentation titled: Unleashing the Allogeneic Potential by Using Large Scale Automated Manufacturing Platforms on Wednesday, March 20, 2024 at 2:40 PM.
Pluri’s Chief Commercial Officer PluriCDMO Andy Lewin will attend the event.
The Advanced Therapies congress is Europe’s largest cell and gene therapy conference and exhibition. The event brings together the world leaders in advanced therapy medicinal product development and the most senior executives in charge of the latest tech and strategies that are driving the industry forward.
Conference: CISH Impact Investments Holdings Conference
Date: March 28, 2024 Location: Online Event
Pluri’s Chief Executive Officer & President Yaky Yanay will be presenting at the conference on Thursday, March 28, 2024 at 2:20 PM.
CISH Impact Investments Holdings Conference is a global event on impact opportunities and investments in promising technology companies that have a positive impact on the community and the environment.
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com/ Jessica Daitch at Jessica@quantum-corp.com
PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
HAIFA, Israel – March 14, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell- free therapeutics for complex fibrotic conditions.
PluriCDMO™ will support Remedy Cell’s production team in the manufacturing of a clinical- grade Working Cell Bank (WCB) and GMP batches of Remedy Cell’s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Remedy Cell CEO, Ayelet Dilion-Mashiah, said, “This is an exciting time at Remedy Cell as we initiate the early stages of clinical development of our novel drug candidate, RC-0315, for IPF, a condition with significant unmet treatment needs. We look forward to the manufacture of our drug candidate at Pluri’s GMP facilities and believe that their vast experience developing and manufacturing cell therapies will accelerate our time to market.”
Pluri CEO and President, Yaky Yanay, said, ”Remedy Cell is an innovative company developing crucial treatments like RC-0315 to address complex conditions with limited therapeutic options. We are delighted that Remedy Cell has chosen PluriCDMO™ to assist with their clinical manufacturing, and we eagerly anticipate the establishment of a robust, long-term partnership grounded in excellence and collaboration.”
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Pluri launched its CDMO division in January 2024, leveraging its proprietary knowledge, cutting- edge technology and cell therapy production facility on behalf of clients. PluriCDMO™ clients gain access to Pluri’s state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables 3D cell expansion at mass scale via a fully controlled, automated and validated process.
For more information visit www.pluri-biotech.com/cdmo or contact CDMO@Pluri- biotech.com
Remedy Cell Ltd., a biopharmaceutical company, harnesses scientific advancements in cell- derived therapies to develop first-in-class, breakthrough treatments for patients suffering from complex fibrotic diseases.
The company’s lead product RC-0315 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) has accomplished very encouraging pre-clinical results and it aims to reach first in human in early 2025. IPF is a serious chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs. IPF is an Orphan Disease that affects 100,000 patients in the US and approximately 110,000 patients in Europe.
There is currently no cure and IPF patients are not likely to survive beyond 2-5 years from diagnosis.
There is an urgent need for a therapeutic treatment option that effectively degrades fibrosis and restores lung function.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses that it anticipates the establishment of a robust, long-term partnership grounded in excellence and collaboration with Remedy Cell.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product
HAIFA, Israel – March 11, 2024 – In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”) today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” represents a major breakthrough in Pluri’s proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions.
An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with 98% less water and 95% less growing area. Pluri’s patent and 3D cell expansion technology can also potentially address an emerging gap in agricultural healthcare, as approximately one-fifth of the 50,000 medical plants used today are on a list of threatened species.
The global cellular agriculture market was valued at $133 billion in 2021 and is projected to grow to $515 billion by 2030. This growth trajectory potentially positions Pluri’s newly patented technology as a potentially transformative force within this important industry. Yaky Yanay, Pluri’s Chief Executive Officer and President said: “This key patent not only solidifies our leadership in cell expansion technology but also aligns with our strategic vision to scale the production of cell-based products industrially, potentially opening a broad spectrum of market opportunities.”
With over 140 active and granted patents, Pluri’s robust IP portfolio is a testament to its pioneering role in the agtech industry. This patent, secured from the Israel Patent Office, further enhances Pluri’s competitive positioning through innovative contributions to sustainable agriculture and beyond.
“We believe this patent positions Pluri as a leader in cell expansion technology for the agtech industry.” stated Mr. Yanay. “PluriAgtech’s patented technology can be used for a wide range of plant cell products like food and beverages, medicine, ingredients and more. We see many opportunities in the agtech space, where Pluri is on the forefront of providing sustainable solutions for humanity’s greatest challenges both through our own proprietary products and in conjunction with potential partners.”
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses its belief that its patent represents a major breakthrough in Pluri’s proprietary 3D bioreactor technology, the potential uses and benefits of its technologies and products, the growth projections for the global cellular agriculture market, that its newly patented technology is a potentially transformative force within its industry, its belief that cell expansion has the potential to become a major driver and future pillar of agtech, and the potential opportunities in the agtech space.. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
HAIFA, Israel, March 6, 2024– Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.
Having served in public-service positions in Washington, D.C., followed by a successful decade in the private sector as CEO of Tufts Health Plan, Mr. Roosevelt is a trusted and sought-after advisor on business matters, legislative and regulatory issues, governance, and personnel matters. The intersection of public policy and health is a passion for him. As CEO of Tufts Health Plan, his leadership achieved consistent profitability while attaining the #1 ranking from the National Committee for Quality Assurance.
“My career advocating for equitable access to quality healthcare is informed by my belief that we can never stop innovating as we search for new approaches and therapeutics for patients. I am excited to join Pluri’s Advisory Board to provide advice and inspiration that will advance their mission of developing new cell-based, sustainable treatments targeting populations with unmet medical needs, using their remarkable 3D cell expansion platform,” said Mr. Roosevelt.
Bringing his expertise to Pluri’s Advisory Board, Mr. Roosevelt will contribute to the Company’s strategic growth plans, particularly in the area of regenerative medicine, by advising on longevity opportunities, best practices for securing and maintaining ongoing grants and contracts with U.S. government agencies, and facilitating relationships with investors and partners.
“An inspiring leader, Jim has devoted his career to protecting peoples’ health in both the public and private sector, always advocating for improved access to health care,” said Pluri CEO and President Yaky Yanay. “Given his knowledge and excitement about the potential of regenerative medicine and our proprietary technology, he will surely contribute to our future growth.”
“We welcome Jim to our Advisory Board and look forward to incorporating his insights and strategies. Together, we will advance our understanding of how our groundbreaking cell therapies targeting a variety of medical indications will lead to more personalized and well-tolerated treatments,” added Zami Aberman, chairman of the board at Pluri.
Before joining Tufts Health Plan, Mr. Roosevelt served as associate commissioner of the U.S. Social Security Administration and is a national speaker and published author writing about the Affordable Care Act, Medicare and Medicaid policy, and Social Security. He has also been a visiting fellow at the Institute of Politics of the Harvard Kennedy School of Government and continues as a clinical instructor in the Public Health and Community Medicine Department of Tufts University School of Medicine.
In the tradition of his grandfather and other members of the Roosevelt family, Mr. Roosevelt co-chairs the Rules and Bylaws Committee of the Democratic National Committee and serves as volunteer legal counsel for the Massachusetts Democratic Party. Mr. Roosevelt is also a trustee of the Cambridge Public Library, the Cambridge Community Foundation, and the Atrius Health Equity Foundation. In the past, he has co-chaired Rhode Island Governor Gina Raimondo’s Health-Care Leaders Task Force on Health-Care Cost Growth and the Massachusetts Hospital Association’s work group on access to behavioral health care.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food- tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production.
Pluri also offers CDMO services.
To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward- looking statements when it discusses its mission of developing new cell-based, sustainable treatments targeting populations with unmet medical needs, using its 3D cell expansion platform; its growth plans and Mr. Roosevelt’s contribution to its future growth; the advancement of its understanding of how cell therapies targeting a variety of medical indications will lead to more personalized and well-tolerated treatments.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum- corp.com
HAIFA, Israel – February 28, 2024 – Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President, Yaky Yanay:
Dear Fellow Shareholders,
As we move into 2024, I’m proud to share my thoughts about all the exciting things happening at Pluri right now.
As a purpose-driven company with goal-oriented leadership and a deep commitment to our shareholders, we enter 2024 with significant momentum in every area of our business, validating our approach and demonstrating strong execution.
Over the past several months, we’ve launched PluriAgtech, a new business vertical focused on applying our cell- based technologies to improve agriculture; and PluriCDMO, a contract development and manufacturing organization (CDMO) division, with the goal to drive revenues and cash flow while continuing to advance healthcare therapeutics.
We are building long-term strategic alliances and partnerships with companies that are leaders in their respective fields, have market access, employ a similar approach to innovation, and are committed to pioneering a biotech revolution with us, with the goal to accelerate time to market.
Despite the myriad of challenges associated with scaling a business during these difficult times, the last few months have been especially exciting for Pluri, bringing significant progress in multiple areas.
Just as Israel has demonstrated resilience, Pluri has also demonstrated immense strength over the last few months, showing our partners and customers that we deliver innovation no matter what the current circumstances are. In fact, we’re coming off a year of successes that offer a glimpse of the bright future ahead for Pluri:
In January 2024, we launched our cell-based coffee business, pioneering a new and game- changing way to address the rapidly growing $130 billion coffee industry in a more sustainable, eco-friendly way. The coffee industry is currently at risk as global warming is expected to slash the amount of land available for coffee production by up to 50% by 2050.
Leveraging our proprietary 3D technology platform, our new vertical PluriAgtech can create high-quality cell-based coffee with 98% less water than traditional coffee production. We also estimate that our innovative new production process will reduce the amount of growing area by 95%, potentially preventing deforestation.
We are receiving a lot of interest from partners and strategics around this unique project, that can potentially transform and solve some main challenges of the industry.
Our goal is to build our cell- based coffee business as a new subsidiary focused on the coffee industry and we are working to secure sufficient funding to support the development process, scaleup and regulatory phase.
In January 2024, we launched our CDMO division, to provide services to innovative biotech companies in the rapidly growing $5.2 billion cell and gene therapy sector.
PluriCDMO includes not only our experienced clinical and bio-manufacturing team but also our robust Good Manufacturing Practice (GMP) facility and our proprietary 3D cell-expansion technology. We believe PluriCDMO can be the launchpad so many companies need to take their cell and gene therapies to the next level.
While we already started generating revenues from this division, we are receiving a lot of additional interest and are currently negotiating several CDMO agreements. PluriCDMO provides substantial value to our clients by offering; access to extensive knowledge, mass scale production opportunities and expedited time to market. We expect this division to boost Pluri’s revenues and cash flow through the utilization of our well-established technology and GMP- certified facility.
Russia’s invasion of Ukraine and Vladmir Putin’s dangerous rhetoric have raised the specter of nuclear war, and the global medical community must prepare for the worst-case scenario.
Unfortunately, the world remains unprepared for a nuclear attack or a major accident. Medical responses to nuclear radiation poisoning have failed to keep pace, while nuclear weaponry has grown exponentially more powerful since World War II.
In July 2023, we signed a 3-year, $4.2 million contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of our PLX-R18 cell therapy as a potential novel treatment for Hematopoietic Acute Radiation Syndrome (H-ARS). We are collaborating with the U.S. Department of
Defense’s (DoD) Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS) in Maryland.
PLX-R18 is being developed with the intention of being eligible for purchase by the U.S. Strategic National Stockpile as a medical countermeasure for exposure to nuclear radiation, following U.S. Food and Drug Administration (FDA) approval.
Another example of executing our partnered-based strategy is the agreement we signed with BIRAD, the commercial division of Bar-Ilan University. BIRAD – Research & Development Company has the right to further develop and commercialize PLX cells as a product to treat cocaine addiction and Pluri is entitled to a 20% revenue share from future sales of the product.
The lack of any FDA-approved medications to treat cocaine addiction presents a significant opportunity in a critical health area with significant unmet need.
We expect that additional partnership agreements will continue to drive our current PluriHealth pipeline to commercialization.
Within one year of its establishment, Ever After Foods announced a 700% increase in productivity compared to other cultivated meat companies, showing the great promise of our technology when it comes to scale and cost parity. Ever After Foods’ long-term goal is to serve as a technology enabler for the broader industry.
Ever After Foods is led by a stellar management and operational team and we expect to share some exciting developments over the coming months.
We believe our technology is pivotal for solving some of the most important trials facing humanity today. As a global leader in cell-based technology, Pluri is setting the stage for a future full of hope in the areas of food security, climate change, sustainability, health and aging.
Today I am proud to say that we are building the strongest pipeline of collaborations and negotiations that we’ve ever had. By creating novel cell-based products both independently and through partnerships, Pluri is showing what’s possible when we all work together. As such, our transformative technology is not only creating long-term value for our shareholders; it’s also making the world a better place. Thank you for your support.
Best regards,
Yaky Yanay
Chief Executive Officer and President, Pluri Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the potential benefits of its various products, its goals relating to its coffee business, the belief that PluriCDMOTM can be a launchpad for companies needing assistance with their cell and gene therapies, that it aims to build its cell-based coffee business as a new subsidiary and is working to secure sufficient funding to support the development process, scaleup and regulatory phase, that it is negotiating several CDMO agreements, that it expects its CDMO business to boost its revenues and cash flow, that it expects that additional partnership agreements will continue to drive its current PluriHealth pipeline to commercialization and that it expects Ever After Foods to share exciting developments over the coming months.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
HAIFA, Israel, January 23, 2024 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global well-being and sustainability, announced today that it has launched its cell-based coffee business activity, an innovative product that will potentially revolutionize the traditional coffee industry.
Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production.
Pluri is pioneering plant cell-based, industrial scale manufacturing solutions for the coffee industry, leveraging its 3D cell expansion technology to create high quality coffee under the Company’s new business vertical, PluriAgtech. PluriAgtech aims to forge a brighter, greener future for agriculture by using breakthrough cell technology to create more eco-friendly alternatives to traditional farming methods.
PluriAgtech’s cell-based coffee has been developed to deliver authentic coffee while solving key challenges faced by the industry.
Compared to traditional methods of coffee production, Pluri’s cell-based coffee is estimated to slash water usage by 98%.
This innovation promises to confront the reduction of suitable growing areas that are expected to decline by up to 50% by 2050; reduce price instability in a traditional commodity market; and minimize the environmental impact of coffee production, as current production methods have a high carbon footprint and upcoming regulations are expected to further strain producers. While coffee production challenges persist, world demand for coffee is expected to triple by 2050.
Pluri’s goal is to spin out its cell-based coffee as a new subsidiary focused on developing innovative products, technologies and intellectual property for the coffee industry. This new planned subsidiary will be led by Michal Ogolnik, a dynamic, results-driven business leader. She has over 20 years of executive management experience in the pharma and energy sectors.
“We are uniquely positioned to transform the coffee industry with our sustainable cell-based coffee,” said Michal Ogolnik.
“By harnessing the power of Pluri’s cutting-edge technology, we could create a brighter, more sustainable future for our planet. By bringing innovation to the forefront, we can tackle some of the coffee industry’s most pressing challenges.”
“We believe deeply in the power of cell technology to make farming and food cultivation more productive and sustainable. Pluri’s advanced agtech solutions potentially reduce the environmental footprint of traditional agricultural production. PluriAgtech can deliver numerous solutions ranging from products like cell-based coffee to bioactive in order to address the biggest challenges in agriculture,” said Pluri CEO and President Yaky Yanay. “We see great interest in the development of additional cell-based products under the PluriAgtech vertical from potential partners. We are excited about the opportunities presented by cell- based coffee.”
To learn more about Pluri’s cell-based coffee visit our website.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri uses forward-looking statements when it discusses the intended use of its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtech; the growth of the coffee industry; the potential benefits of PluriAgtech and its potential to address issues in the coffee market, as well as the environment; its belief that its cell-based coffee product will revolutionize the traditional coffee industry and address the growing global demand for sustainable, high-quality coffee at mass scale production; the aim of PluriAgtech to forge a brighter, greener future for agriculture by using breakthrough cell technology to create more eco-friendly alternatives to traditional farming methods; Pluri’s goal to spin out its cell-based coffee as a new subsidiary focused on developing innovative products, technologies and IP for the coffee industry; that its technology could create a brighter, more sustainable future for the planet; its collaborations with current and potential strategic partners; its aim to develop cutting- edge products and technology; and its ability to address the biggest challenges in agriculture. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its proposed plans, including research and developmentry; its products may not be approved by regulatory agencies; its technology may not be validated as it progresses further and its methods may not be accepted; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real world settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Brianna Ziegler at brianna@miller-ink.com
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.